ArticleJournal of cancer research and clinical oncology2023

Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial.

Aidong Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.